U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Central Nervous System Non-Hodgkin Lymphoma

MedGen UID:
1636859
•Concept ID:
C4687630
•
Neoplastic Process

Definition

A central nervous system non-Hodgkin lymphoma which does not respond to treatment. [from NCI]

Professional guidelines

PubMed

Treatment Options for Recurrent Primary CNS Lymphoma.
Kaulen LD, Baehring JM
Curr Treat Options Oncol 2022 Nov;23(11):1548-1565. Epub 2022 Oct 7 doi: 10.1007/s11864-022-01016-5. PMID: 36205806
Evidence-based expert consensus on the management of primary central nervous system lymphoma in China.
Chen T, Liu Y, Wang Y, Chang Q, Wu J, Wang Z, Geng D, Yu JT, Li Y, Li XQ, Chen H, Zhuang D, Li J, Wang B, Jiang T, Lyu L, Song Y, Qiu X, Li W, Lin S, Zhang X, Lu D, Lei J, Chen Y, Mao Y
J Hematol Oncol 2022 Sep 29;15(1):136. doi: 10.1186/s13045-022-01356-7. PMID: 36176002Free PMC Article
Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma.
Moleti ML, Testi AM, Foà R
Br J Haematol 2020 Jun;189(5):826-843. Epub 2020 Mar 6 doi: 10.1111/bjh.16461. PMID: 32141616

Recent clinical studies

Etiology

Treatment Options for Recurrent Primary CNS Lymphoma.
Kaulen LD, Baehring JM
Curr Treat Options Oncol 2022 Nov;23(11):1548-1565. Epub 2022 Oct 7 doi: 10.1007/s11864-022-01016-5. PMID: 36205806
Rituximab-Lenalidomide-Ibrutinib Combination for Relapsed/Refractory Primary CNS Lymphoma: A Case Series of the LOC Network.
Houillier C, Chabrot CM, Moles-Moreau MP, Willems L, Ahle G, Waultier-Rascalou A, Fornecker LM, Hoang-Xuan K, Soussain C
Neurology 2021 Sep 28;97(13):628-631. doi: 10.1212/WNL.0000000000012515. PMID: 34580183
Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma.
Moleti ML, Testi AM, Foà R
Br J Haematol 2020 Jun;189(5):826-843. Epub 2020 Mar 6 doi: 10.1111/bjh.16461. PMID: 32141616
Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†.
Ghesquieres H, Chevrier M, Laadhari M, Chinot O, Choquet S, Moluçon-Chabrot C, Beauchesne P, Gressin R, Morschhauser F, Schmitt A, Gyan E, Hoang-Xuan K, Nicolas-Virelizier E, Cassoux N, Touitou V, Le Garff-Tavernier M, Savignoni A, Turbiez I, Soumelis V, Houillier C, Soussain C
Ann Oncol 2019 Apr 1;30(4):621-628. doi: 10.1093/annonc/mdz032. PMID: 30698644
Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
Enting RH, Demopoulos A, DeAngelis LM, Abrey LE
Neurology 2004 Sep 14;63(5):901-3. doi: 10.1212/01.wnl.0000137050.43114.42. PMID: 15365145

Diagnosis

Treatment Options for Recurrent Primary CNS Lymphoma.
Kaulen LD, Baehring JM
Curr Treat Options Oncol 2022 Nov;23(11):1548-1565. Epub 2022 Oct 7 doi: 10.1007/s11864-022-01016-5. PMID: 36205806
Primary central nervous system lymphoma.
Schaff LR, Grommes C
Blood 2022 Sep 1;140(9):971-979. doi: 10.1182/blood.2020008377. PMID: 34699590Free PMC Article
How we treat primary central nervous system lymphoma.
Calimeri T, Steffanoni S, Gagliardi F, Chiara A, Ferreri AJM
ESMO Open 2021 Aug;6(4):100213. Epub 2021 Jul 13 doi: 10.1016/j.esmoop.2021.100213. PMID: 34271311Free PMC Article
Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma.
Moleti ML, Testi AM, Foà R
Br J Haematol 2020 Jun;189(5):826-843. Epub 2020 Mar 6 doi: 10.1111/bjh.16461. PMID: 32141616
Primary CNS Lymphoma.
Grommes C, DeAngelis LM
J Clin Oncol 2017 Jul 20;35(21):2410-2418. Epub 2017 Jun 22 doi: 10.1200/JCO.2017.72.7602. PMID: 28640701Free PMC Article

Therapy

Treatment Options for Recurrent Primary CNS Lymphoma.
Kaulen LD, Baehring JM
Curr Treat Options Oncol 2022 Nov;23(11):1548-1565. Epub 2022 Oct 7 doi: 10.1007/s11864-022-01016-5. PMID: 36205806
Primary central nervous system lymphoma.
Schaff LR, Grommes C
Blood 2022 Sep 1;140(9):971-979. doi: 10.1182/blood.2020008377. PMID: 34699590Free PMC Article
How we treat primary central nervous system lymphoma.
Calimeri T, Steffanoni S, Gagliardi F, Chiara A, Ferreri AJM
ESMO Open 2021 Aug;6(4):100213. Epub 2021 Jul 13 doi: 10.1016/j.esmoop.2021.100213. PMID: 34271311Free PMC Article
Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma.
Moleti ML, Testi AM, Foà R
Br J Haematol 2020 Jun;189(5):826-843. Epub 2020 Mar 6 doi: 10.1111/bjh.16461. PMID: 32141616
Primary CNS Lymphoma.
Grommes C, DeAngelis LM
J Clin Oncol 2017 Jul 20;35(21):2410-2418. Epub 2017 Jun 22 doi: 10.1200/JCO.2017.72.7602. PMID: 28640701Free PMC Article

Prognosis

Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy.
Roschewski M, Hodson DJ
Haematologica 2024 Feb 1;109(2):388-400. doi: 10.3324/haematol.2021.278613. PMID: 37706315Free PMC Article
Lymphomas mimicking neuroinflammatory diseases - A diagnostic conundrum worth revisiting.
Raza SA, Raza M, Dai M, Husan A, Cotelingam J, AlHussein H
J Neuroimmunol 2022 Nov 15;372:577970. Epub 2022 Sep 15 doi: 10.1016/j.jneuroim.2022.577970. PMID: 36137305
Primary central nervous system lymphoma.
Schaff LR, Grommes C
Blood 2022 Sep 1;140(9):971-979. doi: 10.1182/blood.2020008377. PMID: 34699590Free PMC Article
Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma.
Moleti ML, Testi AM, Foà R
Br J Haematol 2020 Jun;189(5):826-843. Epub 2020 Mar 6 doi: 10.1111/bjh.16461. PMID: 32141616
Primary CNS Lymphoma.
Grommes C, DeAngelis LM
J Clin Oncol 2017 Jul 20;35(21):2410-2418. Epub 2017 Jun 22 doi: 10.1200/JCO.2017.72.7602. PMID: 28640701Free PMC Article

Clinical prediction guides

Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients.
Cook MR, Dorris CS, Makambi KH, Luo Y, Munshi PN, Donato M, Rowley S, Saad A, Goy A, Dunleavy K, Ali A
Blood Adv 2023 Jan 10;7(1):32-39. doi: 10.1182/bloodadvances.2022008525. PMID: 36260735Free PMC Article
Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.
Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y, Yonezawa H, Asai K, Fukuhara N, Sugiyama K, Shinojima N, Kitagawa J, Aoi A, Nishikawa R
Neuro Oncol 2021 Jan 30;23(1):122-133. doi: 10.1093/neuonc/noaa145. PMID: 32583848Free PMC Article
Central Nervous System Lymphomas.
Grommes C
Continuum (Minneap Minn) 2020 Dec;26(6):1476-1494. doi: 10.1212/CON.0000000000000936. PMID: 33273169
Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†.
Ghesquieres H, Chevrier M, Laadhari M, Chinot O, Choquet S, Moluçon-Chabrot C, Beauchesne P, Gressin R, Morschhauser F, Schmitt A, Gyan E, Hoang-Xuan K, Nicolas-Virelizier E, Cassoux N, Touitou V, Le Garff-Tavernier M, Savignoni A, Turbiez I, Soumelis V, Houillier C, Soussain C
Ann Oncol 2019 Apr 1;30(4):621-628. doi: 10.1093/annonc/mdz032. PMID: 30698644
Prognostic impact of activation-induced cytidine deaminase expression for patients with diffuse large B-cell lymphoma.
Arima H, Fujimoto M, Nishikori M, Kitano T, Kishimoto W, Hishizawa M, Kondo T, Yamashita K, Hirata M, Haga H, Takaori-Kondo A
Leuk Lymphoma 2018 Sep;59(9):2085-2095. Epub 2017 Dec 18 doi: 10.1080/10428194.2017.1410884. PMID: 29251015

Recent systematic reviews

Chimeric Antigen Receptor T - Cell Therapy for Large B-Cell Lymphoma Patients with Central Nervous System Involvement, a Systematic Review and Meta-analysis.
Elgohary G, Yang Y, Gergis M, Yi D, Gergis U
Clin Lymphoma Myeloma Leuk 2024 Apr;24(4):e142-e151. Epub 2024 Jan 12 doi: 10.1016/j.clml.2023.12.012. PMID: 38267353
Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review of Literature.
Asghar N, Masood A, Dhaliwal A, Khurana S, Davis J, Hashmi H, Husnain M
Clin Lymphoma Myeloma Leuk 2023 Jan;23(1):15-21. Epub 2022 Oct 7 doi: 10.1016/j.clml.2022.09.008. PMID: 36328891
Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients.
Cook MR, Dorris CS, Makambi KH, Luo Y, Munshi PN, Donato M, Rowley S, Saad A, Goy A, Dunleavy K, Ali A
Blood Adv 2023 Jan 10;7(1):32-39. doi: 10.1182/bloodadvances.2022008525. PMID: 36260735Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...